title: Regional therapies for in-transit disease.
abstract: In-transit melanoma is an uncommon pattern of recurrence, but presents unique management challenges and opportunities for treatment. The clinical presentation usually involves from 1 to more than 100 small subcutaneous or cutaneous nodules, ranging from submillimeter to multiple centimeters in diameter. Regional chemotherapy techniques are a mainstay of treatment of patients without systemic disease spread. Future applications of regional therapy are likely to involve combination therapy with cytotoxic agents and novel immune modulators. Regional therapy provides distinct opportunities for the treatment of unresectable disease, and offers a unique platform for investigation of novel therapeutics in early-stage clinical trials.
authors.affiliation: Department of Surgery, Duke University Medical Center, 2301 Erwin Road, Durham, NC 27710, USA.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Speicher
authors.affiliation: Department of Surgery, Duke University Medical Center, 2301 Erwin Road, Durham, NC 27710, USA.
authors.forename: Claire H
authors.initials: CH
authors.lastname: Meriwether
authors.affiliation: Department of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA. Electronic address: doug.tyler@duke.edu.
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Tyler
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion; D006801:Humans; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: In-transit melanoma; Isolated limb infusion; Isolated limb perfusion; Regional therapy